New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory...
COPENHAGEN, Denmark--(BUSINESS WIRE)--Dec 9, 2023--
COPENHAGEN, Denmark--(BUSINESS WIRE)--Dec 9, 2023--